Interplay of kidney function and anti-SARS-CoV-2 antibodies in COVID-19 mortality: a prospective cohort study.

Publication date: Jul 10, 2025

CKD has been recognized as an independent risk factor for severe disease and death in COVID-19. Given the high variability in humoral responses, their general decrease in strength, quality, and durability with age, and the decline of antibody levels over time, personalized vaccination regimes would ensure optimal protection of patients with CKD. This prospective, multicenter cohort study included 1112 hospitalized COVID-19 patients from five study centers. Anti-SARS-CoV-2-spike antibodies and eGFR were measured on hospital admission. The primary outcome was all-cause in-hospital mortality. Reduced kidney function combined with anti-SARS-CoV-2 spike antibody levels was a stronger predictor of COVID-19 mortality than either parameter separately. After adjusting for potential confounders, patients with an eGFR of 60-89 ml/min, 30-59 ml/min, and 

Open Access PDF

Concepts Keywords
59ml Aged
Antibodies Aged, 80 and over
Covid Anti-SARS-CoV-2 spike antibodies
Kidney Antibodies, Viral
Vaccination Antibodies, Viral
CKD
Correlate of protection
COVID-19
COVID-19
Female
Glomerular Filtration Rate
Hospital Mortality
Humans
Kidney function
Male
Middle Aged
Prospective Studies
Renal Insufficiency, Chronic
Risk Factors
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Vaccination

Semantics

Type Source Name
disease MESH COVID-19
disease MESH death
disease IDO quality
disease MESH Renal Insufficiency Chronic

Original Article

(Visited 2 times, 1 visits today)